Cambridge Healthcare Research (CHR) is expanding its team of strategic advisers with the appointment of former Pfizer director Marjorie Norman to the board.
Marjorie recently retired from the global pharmaceutical giant after 17 years as director of worldwide competitive intelligence. She joins CHR as it embarks on a new phase of growth to meet record demand for its services, which inform decision makers with product strategy and commercialisation.
She has 30 years’ experience in business and competitive intelligence, strategic development, competitive benchmarking and market research in corporate, consulting and entrepreneurial environments.
“Marjorie has been a fantastic mentor to us as a company,” said Edward Cartwright, a partner at CHR. “It will be a real privilege for us to have access to her wisdom and expertise, which will help us to continue to be one of the leading firms in this industry. With her guidance, we will continue delivering work above and beyond our clients’ expectations.”
Marjorie’s appointment comes hot on the heels of Laura Lawrence, formerly of Goldman Sachs, joining CHR as head of operations, and Stella Wooder, chair at Team Consulting, joining the CHR board as a strategic adviser.
